Reach out to our team

On 3 December, Dries will be joining the panel on the "European Health Data Space (EHDS): collaboration and partnerships for successful implementation" at Health Tech Forward in Barcelona. Together, we can build a trusted, data-driven ecosystem that accelerates research, innovation, and better patient care across Europe.

Meet us at ESMO AI & Digital Oncology 2025. Dr. Annelies Verbiest (UZA) will be presenting our poster 104P: Large-scale characterization of real-world adverse events (AE) on immune checkpoint inhibitors (ICI), while Clara. L. Oeste will be giving a Mini Oral Presentation 176MO: What unstructured EHR data via natural language processing adds to oncology RWE: a multi-center OMOP-CDM assessment in lung cancer.

Meet us at ISPOR Europe 2025 this November as we join the global conversation on real-world evidence and health economics. Book a meeting now! Fabienne Ver Donck will be presenting our poster "Development and Validation of an Automated Cancer Stage Classifier for Real-World Oncology Data Mapped to OMOP CDM".

We'll be at ESMO 2025 in Berlin! Don't miss out on our joint poster: "Comprehensive characterization of evolving immune checkpoint inhibitor (ICI) indications and outcomes through automated standardization of multicenter EHR data".

We are thrilled to announce our participation as a Gold Sponsor at the 2025 OHDSI Europe Symposium, taking place from July 5-7. We will present our poster “Sentinel: Advancing Automated Data Quality Checks in OHDSI Networks"! Sentinel showcases our approach to automating EHR data quality monitoring across OMOP-CDM networks - combining NLP, benchmarking, and interactive dashboards. We look forward engaging with fellow health tech innovators, hospitals, and life sciences organizations to shape the future of health data science.

On 26 March, at the European Lung Cancer Congress, Dr. Decoster (UZ Brussels) will be presenting the joint poster "Real-World Biomarker Testing and Treatment Patterns in Belgian Lung Cancer Patients: Insights from the AIBED Study". This first-of-its-kind Belgian study uses AI and NLP to deliver comprehensive real-world insights into lung cancer patient trajectories, bridging the gap between clinical trial results and patient care in routine practice.

On January 31st, at the Belgian Society of Molecular Oncology, Dr. Nuytemans (AZ Groeninge) unveiled the insights from a Belgian multi-center real-world study in breast cancer patients. This study delved into the distribution of breast cancer molecular subtypes and their clinical characteristics at both diagnosis and after relapse or progression. By harnessing routinely collected hospital data and cutting-edge artificial intelligence technologies within a federated model, this study may lead to a better understanding of the Belgian breast cancer population during their disease course.

We will be attending ISPOR Europe 2024 in Barcelona. Meet our dream team at booth 1126, and discover real-world data use cases in oncology, cardiology and psychiatry, learn more about our European hospital data network and explore the potential of our state-of-the-art proprietary NLP pipeline.

We are attending the 10th annual OHDSI Global symposium.

We will be attending the OHDSI UK symposium in London!

Join us at the ESMO Congress 2024 from 13-17 September in Barcelona, and discover our 2 posters on (i) the real-world usage and adverse events of immune checkpoint inhibitors, and (ii) cardiovascular toxicities in real-world cancer patients treated with immune checkpoint inhibitors.

Meet us at OHDSI Europe 2024 workshops and symposium! On 3 June, Dr. Annelies Verbiest (UZA) and Clara L. Oeste (LynxCare) will provide insights into our Belgian oncology research network and present the initial results from a study into Lung Cancer patients treated with immune checkpoint inhibitors (ICI).